Abstract
Type 2 diabetes (T2D) shows a high mortality rate, dependent on disease duration, comorbidities and glucose control over time. Data on patients with short disease duration are scanty. We prospectively followed a cohort of newly-diagnosed T2D patients referring to a single diabetes centre, treated according to the international guidelines and checked every 6-12 months. All-cause mortality and major cardiovascular (CV) events were registered. 289 patients out of 3019 consecutive first attendances matched inclusion criteria and were included in the observation. Mean follow-up was 51.2 months. At 31 December 2018, 253 patients were alive and 36 deceased. At baseline, deceased individuals were older, with lower eGFR and lower uric acid, higher prevalence of atrial fibrillation. During the follow-up, 18 non-fatal CV events were adjudicated; patients with incident CV disease (CVD) differed at baseline for sex, previous history of CVD and retinopathy, higher use of secretagogues and lower use of metformin. At multivariate analysis, age and previous CVD were the only independent determinants of all-cause mortality and incident CVD, respectively. In deceased individuals, eGFR slope was markedly unstable and ΔeGFR at the end of the follow...Continue Reading
References
Aug 29, 2006·Diabetes Care·Nicholas L SmithBruce M Psaty
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Mar 27, 2010·Journal of the American College of Cardiology·Earl S FordChaoyang Li
Mar 16, 2011·Archives of Internal Medicine·S Goya WannametheeNaveed Sattar
Aug 10, 2011·The American Journal of Cardiology·Ralph A DeFronzo, Muhammad Abdul-Ghani
Nov 15, 2011·Diabetes Research and Clinical Practice·David R WhitingJonathan Shaw
Jan 18, 2012·Clinical Endocrinology·Safak AkınAlper Gürlek
Dec 11, 2013·JAMA Internal Medicine·Elbert S HuangAndrew J Karter
Aug 17, 2014·The Lancet. Diabetes & Endocrinology·Edward W GreggTheodore J Thompson
Sep 18, 2014·Diabetologia·Sophia ZoungasUNKNOWN ADVANCE Collaborative group
Sep 19, 2014·Annals of Medicine·Yi HuangYunzhao Hu
Apr 14, 2015·Annals of Internal Medicine·Shelley SelphRoger Chou
Sep 18, 2015·The Lancet. Diabetes & Endocrinology·UNKNOWN Diabetes Prevention Program Research Group
Oct 29, 2015·The New England Journal of Medicine·Mauro TancrediMarcus Lind
Jul 3, 2016·Diabetes Research and Clinical Practice·Khalid Al-RubeaanKhaled H Aburisheh
Jul 16, 2016·European Journal of Endocrinology·Timothy M E DavisWendy A Davis
Aug 16, 2016·Cardiovascular Diabetology·Angelo AvogaroStefano Del Prato
Nov 25, 2016·BMJ : British Medical Journal·Yuli HuangYunzhao Hu
Apr 8, 2017·Diabetes, Obesity & Metabolism·Salwa S ZghebiDarren M Ashcroft
Jul 20, 2017·Diabetes & Metabolism·S TanakaUNKNOWN Japan Diabetes Complications Study Group
Nov 15, 2017·PloS One·Tai-Chi LinShih-Jen Chen
Dec 8, 2017·BMC Family Practice·Pål JørgensenSiri Forsmo
Feb 24, 2018·Diabetologia·Lili HuoBendix Carstensen
Mar 8, 2018·PloS One·Jing HanXiaoxi Qiao
Mar 27, 2018·Acta Diabetologica·Giuseppe PennoUNKNOWN Renal Insufficiency and Cardiovascular Events (RIACE) Study Group
Mar 28, 2018·Diabetes, Obesity & Metabolism·Emanuela OrsiUNKNOWN Renal Insufficiency and Cardiovascular Events (RIACE) Study Group
Apr 9, 2018·Cardiovascular Diabetology·Gyeongsil LeeSang Min Park
Nov 13, 2018·Kidney International·Guozhi JiangUNKNOWN Hong Kong Diabetes Register TRS Study Group
Apr 9, 2019·Circulation·Naveed SattarSoffia Gudbjörnsdottir
Oct 10, 2019·Diabetes, Obesity & Metabolism·Jonas GhouseJonas B Nielsen